Calidi Biotherapeutics (CLDI) Common Equity (2021 - 2025)

Calidi Biotherapeutics has reported Common Equity for 5 years, with the latest figure at $3.8 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 91.01% year-over-year to $3.8 million; the trailing twelve-month figure through Dec 2025 stood at $3.8 million (up 91.01% YoY), and the FY2025 full-year result was $3.8 million, up 91.01% from the prior year.
• Common Equity for Q4 2025 stood at $3.8 million, down from $7.2 million in the prior quarter.
• The five-year high for Common Equity was $7.3 million in Q1 2025, with the low at -$63.7 million in Q2 2023.
• Average Common Equity over 5 years is -$20.3 million, with a median of -$11.8 million recorded in 2024.
• Year-over-year, Common Equity slumped 795.61% in 2024 and surged 173.46% in 2025.
• Tracing CLDI's Common Equity over 5 years: stood at -$31.6 million in 2021, then tumbled by 59.56% to -$50.4 million in 2022, then jumped by 83.67% to -$8.2 million in 2023, then soared by 123.9% to $2.0 million in 2024, then soared by 91.01% to $3.8 million in 2025.
• The last three Common Equity figures came in at $3.8 million (Q4 2025), $7.2 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.

Peer Comparison